CD47 and cancer: Consistently, Kojima et al. demonstrated that a CD47-blocking antibody originally developed as an anti-cancer drug improves efferocytic removal of apoptotic cells from the vascular wall, leading to attenuated vascular inflammation and atherosclerosis in mice [421].